-+ 0.00%
-+ 0.00%
-+ 0.00%

NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026

Barchart·09/10/2026 07:05:00
Listen to the news

SANTA ANA, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the potential of troculeucel, the Company’s lead investigational program, for the treatment of neurodegenerative diseases at Biologics Manufacturing Korea 2026, taking place September 17-18, 2026, in Incheon, South Korea.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.